Literature DB >> 4026438

An experimental vaccine against American dermal leishmaniasis: experience in the State of Espírito Santo, Brazil.

W Mayrink, P Williams, C A da Costa, P A Magalhães, M N Melo, M Dias, A Oliveira Lima, M S Michalick, E Ferreira Carvalho, G C Barros.   

Abstract

A vaccine prepared from killed and sonicated promastigotes of five Brazilian strains of Leishmania was used during an epidemic of American dermal leishmaniasis that occurred in Viana county, State of Espírito Santo, Brazil. Initially, all of the participants in the vaccination programme had negative reactions to Montenegro antigen. Forty days after the last dose of vaccine had been given, 87.6% of the 216 vaccinated individuals had become Montenegro-positive whereas the 266 unvaccinated persons remained Montenegro-negative. The study area had an unstable population and details are given about the human population changes that occurred during the two-year study period. Taking into account population movements, 1.5% of those vaccinated and 6.4% of the unvaccinated group developed dermal leishmanial lesions by the end of the first year. At the end of the second year, 1.7% of those vaccinated and 8.9% of the unvaccinated group had become infected. The difference in infection rates of the two groups is statistically significant at both the end of the first and second years of observation. Diagnosis of the disease(s) was based on the clinical appearance of lesions combined with parasitological and/or immunological evidence and subsequent responses to treatment. The experience gained in Viana also provided information about the storage and administration of the experimental vaccine which have been used in mounting a randomized clinical trial.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026438     DOI: 10.1080/00034983.1985.11811917

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  10 in total

1.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

2.  T-lymphocytes in experimental Leishmania amazonensis infection: comparison between immunized and naive BALB/c mice.

Authors:  M Pompeu; A L Freitas; G A dosReis; M Barral-Netto
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

3.  Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.

Authors:  F Afrin; N Ali
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Development of an immunogen containing CD4+/CD8+ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis.

Authors:  Isabela de Andrade Ferraz; Ana Maria Ravena Severino Carvalho; Rory Cristiane Fortes de Brito; Bruno Mendes Roatt; Vívian Tamietti Martins; Daniela Pagliara Lage; Luiza Dos Reis Cruz; Fernanda Alvarenga Cardoso Medeiros; Denise Utsch Gonçalves; Manoel Otávio da Costa Rocha; Eduardo Antonio Ferraz Coelho; Tiago Antônio de Oliveira Mendes; Mariana Costa Duarte; Daniel Menezes-Souza
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-27       Impact factor: 5.560

5.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

Review 6.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

Authors:  Eva Iniguez; Nathaniel S Schocker; Krishanthi Subramaniam; Susana Portillo; Alba L Montoya; Waleed S Al-Salem; Caresse L Torres; Felipe Rodriguez; Otacilio C Moreira; Alvaro Acosta-Serrano; Katja Michael; Igor C Almeida; Rosa A Maldonado
Journal:  PLoS Negl Trop Dis       Date:  2017-10-25

Review 8.  A review of preventative methods against human leishmaniasis infection.

Authors:  Lisa Stockdale; Robert Newton
Journal:  PLoS Negl Trop Dis       Date:  2013-06-20

Review 9.  Cutaneous Leishmaniasis Vaccination: A Matter of Quality.

Authors:  Paula Mello De Luca; Amanda Beatriz Barreto Macedo
Journal:  Front Immunol       Date:  2016-04-21       Impact factor: 7.561

10.  Vaccination in Leishmaniasis: A Review Article.

Authors:  Latifeh Abdellahi; Fariba Iraji; Anahita Mahmoudabadi; Seyed Hossein Hejazi
Journal:  Iran Biomed J       Date:  2022-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.